Tag Archives: U.S.

F.D.A. Authorizes E-Cigarettes to Stay on U.S. Market for the First Time

Advertisement Continue reading the main story Supported by Continue reading the main story F.D.A. Authorizes E-Cigarettes to Stay on U.S. Market for the First Time The agency approved three Vuse vaping products and said their benefits in helping smokers quit outweighed the risks of hooking youths. Read in app The Vuse Solo e-cigarette is the… Read More »

The Latest: More U.S. first responders are dying of COVID-19

UNDATED — The resurgence of COVID-19 this summer and the national debate over vaccine requirements have created a fraught situation for the United States’ first responders, who are dying in larger numbers but pushing back against mandates. It’s a stark contrast from the beginning of the vaccine rollout when first responders were prioritized for shots.… Read More »

The Stress of the Caregiver: The Most Over-Utilized, Unpaid Stakeholder in U.S. Healthcare

We’ve long know that “the patient” has been an under-utilized resource in the U.S. healthcare system since Dr. Charles Safran testified with that statement to Congress way back in 2004…an era where bipartisanship for health IT was a real thing. Today, with the insights of Alexandra Drane (Founder of ARCHANGELS) and Dr. Nirav Shah (of… Read More »

U.S. FDA Approves Yescarta for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

SANTA MONICA, Calif.–(BUSINESS WIRE)–Mar. 5, 2021– Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The approval makes Yescarta the first chimeric antigen receptor… Read More »